Abstracts tagged "lipids and metabolism"

Abstract Number: 2702 • 2017 ACR/ARHP Annual Meeting
Tissue-Invasive T Cells in Rheumatoid Arthritis
Cornelia M. Weyand¹, Yi Shen², Yinyin Li¹, Eric L. Matteson³, Stuart Goodman⁴ and Jorg Goronzy⁵, ¹Medicine: Immunology and Rheumatology, Stanford University, Stanford, CA, ²Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Orthopaedic Surgery, Stanford Medical Center Outpatient Clinic, Redwood City, CA, ⁵Medicine/Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: A key pathogenic event in rheumatoid arthritis (RA) is the formation of lasting lymphoid microstructures in the synovial tissue. It requires the transmigration of…
Abstract Number: 2880 • 2016 ACR/ARHP Annual Meeting
Distinct Metabolic Pathways Regulate Lipid Antigen Presentation By Monocytes and B Cells: Implications for SLE Patients with Pre-Clinical Atherosclerotic Plaque
Kirsty Waddington¹, Edward Smith², Sara Croca³, David A. Isenberg⁴, Anisur Rahman⁵, Ines Pineda Torra⁶ and Elizabeth Jury⁷, ¹Clinical Pharmacology and Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology Research, University College London, London, United Kingdom, ³Rheumatology, University College London, London, United Kingdom, ⁴Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, ⁵Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ⁶Clinical Pharmacology, University College London, London, United Kingdom, ⁷Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) patients have an increased risk of developing clinically apparent cardiovascular disease (CVD) and subclinical atherosclerotic plaque, detectable by vascular ultrasound…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].